Objective. To assess whether the presence of nonspecific musculoskeletal symptoms, their degree, and change over time predict the development of psoriatic arthritis (PsA) in a prospective cohort of psoriasis patients without arthritis at baseline.
The idea that disease processes related to rheumatoid arthritis (RA) occur before arthritis is clinically detectable was proposed more than 2 decades ago (10, 11) . Preclinical RA is a topic of active research. It has been found that a significant proportion of RA patients first present with arthralgia and serologic features without having any objective findings on physical examination (e.g., joint swelling). It may be several months to years until these patients develop overt inflammatory arthritis that can be detected on physical examination (12) .
Limited information exists about the presence and characteristics of preclinical phases of PsA. Imaging studies have found that a significant proportion of patients with psoriasis without musculoskeletal symptoms have subclinical arthritis and enthesitis (13, 14) . These abnormalities may predict the development of PsA. Additionally, the prevalence of nonspecific musculoskeletal symptoms without objective findings of PsA on physical examination approaches 30% (15, 16) . Some of these symptoms are attributed to osteoarthritis (OA) or fibromyalgia; however, given the heterogeneous nature of PsA and the difficulties in identifying some of its clinical features, especially in the early phases of the disease, it is possible that some of these patients actually have preclinical PsA. Investigating the characteristics of the preclinical phases of PsA is of great interest now that evidence supports early intervention in PsA. Treating the disease in its preclinical phase may prevent progression to overt PsA. However, it remains a challenge to distinguish patients with true preclinical PsA from psoriasis patients whose symptoms are related to other noninflammatory rheumatic conditions.
In this prospective longitudinal cohort study, we aimed to investigate the presence and characteristics of a preclinical phase of PsA. We hypothesized that this phase would be characterized by the presence of musculoskeletal symptoms without objective findings of PsA. Furthermore, we assessed whether specific combinations of symptoms, their degree, and their change over time predicted the development of PsA in a prospective cohort of psoriasis patients who did not have PsA at baseline.
PATIENTS AND METHODS
Study setting. The University of Toronto Psoriasis Cohort was established in 2006 and forms the basis of a longterm prospective study aimed at assessing risk factors for the development of PsA in patients with psoriasis (17) . All potential study subjects have a diagnosis of psoriasis confirmed by a dermatologist. Patients are mainly recruited from dermatology clinics and phototherapy centers in the Greater Toronto Area, but are also recruited from family practice clinics and through advertisement in flyers posted in several hospitals and local media. Patients with inflammatory arthritis or spondylitis, either in the past or at the time of the assessment, are excluded. All subjects are evaluated by rheumatologists with expertise in assessment of PsA to exclude patients with inflammatory arthritis, enthesitis, or spondylitis before enrollment. At the time of the baseline assessment, each subject undergoes a comprehensive musculoskeletal examination that includes a joint assessment for tenderness (68 joints), swelling (66 joints), and deformities (68 joints), an evaluation for the presence of enthesitis, tendinitis, and dactylitis, and an assessment for restriction of movement in the spine. If there are definite clinical findings of inflammatory arthritis, enthesitis, or spondylitis, the patient is excluded from the study. In cases of diagnostic uncertainty, imaging studies, including radiographs, ultrasound, or magnetic resonance imaging (MRI), are performed as clinically indicated to investigate the nature of the abnormality. Patients thus diagnosed as having psoriasis who have no current evidence or past history of PsA are eligible for the study. If a noninflammatory condition, such as OA or mechanical back pain, is diagnosed, the subject is included in the study. This process ensures that participants do not have clinical inflammatory arthritis at enrollment.
Case definition. All study participants were reassessed annually regardless of whether they had developed musculoskeletal symptoms. Patients were instructed to contact the clinic prior to their annual assessment if they developed symptoms suggestive of PsA (e.g., joint pain or swelling). The process of incident case ascertainment for patients who developed musculoskeletal symptoms was similar to that described above for the baseline visit. The diagnosis of PsA was determined by at least 2 rheumatologists from the PsA research team after reviewing the clinical, laboratory, and imaging data. Participants were classified as having PsA if they fulfilled the Classification of Psoriatic Arthritis (CASPAR) criteria (18) . Patients with nonspecific musculoskeletal symptoms who did not meet the CASPAR criteria continued to be followed up in the psoriasis cohort.
Data collection. Study participants were assessed according to a standard protocol at each visit. The presence of the following musculoskeletal symptoms was recorded by the rheumatologist at each visit: arthralgia, morning joint stiffness, heel pain, back pain, and back stiffness. Furthermore, if back pain was recorded, the physician was asked to determine whether the back pain had inflammatory characteristics based on the Berlin criteria (19) . The duration of morning joint stiffness (in minutes) was also recorded. However, since only 8.3% of the patients reported any morning stiffness, and that was mostly of short duration, we considered only the presence or absence of morning stiffness as a predictor, rather than using the duration as recorded by the physician.
Additionally, at each visit the study participants completed questionnaires estimating several patient-reported outcomes. The following domains were assessed: pain and joint stiffness (both on a 0-10-cm visual analog scale [VAS]) on the Health Assessment Questionnaire, physical function measured by the physical component summary (PCS) score of the Short Form 36 (SF-36) health survey, and psychological distress measured by the mental component summary (MCS) score of the SF-36. Fatigue was measured by the Fatigue Severity Score (FSS), which is a validated 9-point questionnaire that assesses the effect of fatigue on daily activities (20) . We used a modified version of this scale (mFSS) that has been validated in patients with PsA (21) . Each item is scored on a scale of 0-10, as modified from the original scale of 1-7, and an average overall score is computed. A higher score denotes more severe fatigue (22) . An mFSS score of .5 was considered a high fatigue level. The variables described above were categorized as high and low using the following cutoff points: a pain score of .2 on a 0-10-cm VAS was considered high, a stiffness score of .2 on a 0-10-cm VAS was considered high, a physical function score of ,46 on the SF-36 PCS was considered worse physical function, a psychological distress score of ,42 on the SF-36 MCS was considered high distress, and a fatigue score of .5 on the mFSS was considered high. The selected cutoff points for the various domains were the closest round number representing the top quartile of the scores in our cohort. A sensitivity analysis was performed using higher cut points that were the closest round number representing the top 10% of scores in each domain: pain score .5, stiffness score .5, mFSS .7, and SF-36 PCS ,40.
Additional information recorded included demographics, lifestyle habits, family history of psoriasis and rheumatic diseases, comorbidities, and the use of medications. A general physical examination included measurement of height and weight, assessment of psoriasis severity by the Psoriasis Area and Severity Index (PASI), and assessment of the presence and type of psoriatic nail lesions (pitting or onycholysis). A comprehensive musculoskeletal assessment for swelling (66 joints) and tenderness (68 joints) was conducted. The presence and the number of dactylitic digits were recorded. The presence of enthesitis in 18 sites was assessed using the Spondyloarthritis Research Consortium of Canada index (23) .
Statistical analysis. Data are presented as the mean 6 SD for continuous variables and as frequencies and percentages for categorical variables. The association among the various patient-reported outcomes was analyzed using Pearson's correlation coefficients. The number of person-years at risk was calculated as the time between the date of enrollment in the psoriasis clinic and the last date of contact (follow-up visit or death) or the date of PsA diagnosis, whichever came first. For the purpose of this study, only patients who had at least 1 follow-up visit after the initial visit were included in the analysis. Cox proportional hazards models were used to assess predictors of the development of PsA. Explanatory variables included arthralgia, morning joint stiffness, heel pain, any back pain, back stiffness, level of fatigue, level of physical function, level of pain, level of stiffness, and level of psychological distress. These variables were considered primary baseline predictors of PsA in the Cox models, and each of them was included in separate regression models, which were adjusted for age, sex, body mass index (BMI), nail pitting, and PASI. The duration of psoriasis at the time of enrollment was treated as a left-truncation time since subjects were required to be PsA free at entry to the psoriasis clinic. Cox regression models were also fitted using time-varying categorical versions of the primary predictors and using the baseline values and the timevarying differences from the previous assessment to the current assessment for the levels of pain, stiffness, fatigue, and function; the latter were considered to assess the role of recent change in symptoms. We also assessed the interaction between each of the explanatory variables while controlling for key variables (age, sex, BMI, pitting, and PASI).
Since this is the first study to assess the presence of musculoskeletal symptoms in pre-PsA patients, we evaluated a wide range of symptoms as potential predictors of PsA. This analysis was considered exploratory, and no attempt was made to control for multiple testing.
Data on up to 10% of the patient-reported outcome variables were missing (including pain, fatigue, stiffness, physical function, and psychological distress). Missing data were dealt with using multiple imputation (via proc MI and proc minianalyze in SAS) based on predictive mean matching using the full conditional specification; 10 complete data sets were generated by imputation. Statistical analyses were performed using SAS (version 9.3).
RESULTS
Study design. A total of 695 patients with psoriasis were screened. Of those, 84 patients were excluded due to the presence of PsA and other rheumatic conditions at baseline. A total of 611 patients who were followed up from January 1, 2006 to December 4, 2014 were enrolled in the Toronto Psoriasis Cohort. Of those, 201 subjects were excluded from the analysis since they had only a single assessment and did not contribute any follow-up. The characteristics of the excluded patients with PsA were similar to the baseline characteristics of the study population, except that the group of excluded patients was slightly younger (details available upon request from the corresponding author).
Of the 410 patients who were included in the final analysis, 57 patients developed PsA that was confirmed by a rheumatologist. The remaining 353 did not have PsA at their last assessment. This cohort had a total of 1,144 visits, with a mean 6 SD of 45.7 6 25.7 months of follow-up per person (45.6 6 25.3 months for patients who did not Characteristics of the patients. The characteristics of the study population are summarized in Table  1 . The mean 6 SD age of the 57 patients who developed PsA was 49.1 6 13.3 years, 54.4% were men, and the mean duration of psoriasis was 20.1 6 17.2 years. The most frequent pattern of arthritis at presentation was peripheral arthritis (64.2%), followed by axial involvement alone (17.8%), combined peripheral and axial involvement (16.1%), and enthesitis (1.8%). The majority of the patients with peripheral arthritis presented with oligoarthritis (73.3%). Twenty-five percent of the patients who had radiographs of the hands and feet were found to have periarticular erosions. Information about the pattern of arthritis at diagnosis was missing for 1 patient who was diagnosed as having PsA by another rheumatologist outside of the study.
Presence of musculoskeletal symptoms at baseline. Twenty-three percent of the patients reported arthralgia, and 8.3% had morning stiffness. Twelve patients (2.9%) had 1 or more tender joints on physical examination (range 1-11); however, none of them had any swollen joints. Four patients (1%) were found to have a single tender entheseal site. Back pain was reported by 21.5% of the patients, and 2% had inflammatory type back pain. None of the patients with inflammatory back pain had evidence of sacroiliitis or spondylitis by imaging (radiographs in 6 patients and MRI in 2 patients). None of the patients reported having a sausage digit.
Correlations between patient-reported symptoms at baseline. In general, moderate to strong correlation was observed between the different patient-reported outcomes at baseline ( Table 2 ). The strongest correlation was found between pain and 2 domains: stiffness (r 5 0.93) and function (r 5 20.71). Fatigue was moderately correlated with all domains, including psychological distress were associated with the development of PsA independently of known clinical predictors of the disease, including BMI, nail pitting, and PASI (Table 3) . Moreover, there was a significant interaction between sex and arthralgia (P 5 0.02), such that women with arthralgia had an increased risk of PsA (HR 2.59 [95% CI 1.15-5.88]). In a sensitivity analysis (limited to the 5 patient-reported domains) using higher cut points (based on the top 10% of scores) for the patient-reported outcomes, higher levels of fatigue (mFSS .7) (HR 2.51 [95% CI 1.14-5.58]) and stiffness (VAS score .5) (HR 3.19 [95% CI 1.27-8.00]) remained independent predictors of PsA. Additionally, higher levels of pain (VAS score .5) (HR 2.77 [95% 1.12-6.95]) also predicted the development of the disease. The association with lower levels of function and psychological distress were not statistically significant.
Time-dependent predictors. An assessment of the same predictors as time-varying covariates in a Cox regression model showed stronger associations between the Additionally, we assessed whether the extent of change over time from baseline in fatigue, pain, stiffness, psychological distress, and physical function predicted the development of PsA (Table 5) . We hypothesized that the greater the degree and number of symptoms (domains such as fatigue, pain, stiffness), the greater the risk of diagnosis of PsA; multivariable analysis confirmed this hypothesis. For baseline scores, only the levels of fatigue (P , 0.001), stiffness (P 5 0.007), and psychological distress (P 5 0.008) predicted future PsA, while worsening of scores in the following 4 domains compared with baseline predicted the development of PsA: pain (HR 1.34, P , 0.001), fatigue (HR 1.27, P 5 0.001), stiffness (HR 1.21, P 5 0.03), and function (HR 0.96, P 5 0.04) ( Table 5 ). The fact that more variables (domains) measuring the difference in scores from baseline predicted PsA compared to variables (domains) measuring absolute baseline scores suggests that the intensity and the number of symptoms tend to increase in the period prior to the diagnosis of PsA.
DISCUSSION
In this longitudinal study of a unique cohort of psoriasis patients who were followed up prospectively over time, we observed a period of subclinical disease that is characterized by the presence of nonspecific musculoskeletal symptoms in the absence of objective findings suggestive of PsA. The presence of arthralgia in women, heel pain, fatigue, and stiffness are the earlier symptoms associated with subsequent development of PsA in psoriasis patients. Furthermore, an increase in the levels of pain, stiffness, and fatigue, and a worsening of physical function, over time predict the diagnosis of PsA.
Research on the preclinical phases of other rheumatic diseases has gained considerable interest over the past years. However, little is known about the preclinical phases of PsA (the period before musculoskeletal inflammation becomes clinically detectable). Defining preclinical disease in PsA is challenging. The difficulties are related to the heterogeneous nature of PsA, the frequently subtle findings on physical examination, and the overlap with OA and mechanical/overuse soft tissue disorders in many older psoriasis patients. Previous studies have shown that ;50% of the patients with psoriasis who are seen in primary care settings have persistent musculoskeletal symptoms (16) . However, in the majority of cases, the rheumatologist attributed the symptoms to other noninflammatory conditions. The results of our study suggest that the presence of a complex of nonspecific musculoskeletal symptoms in patients with psoriasis may actually represent a preclinical phase of PsA in the absence of objective findings of the disease. High levels of pain and, in particular, fatigue and stiffness were present as long as 6 years prior to the diagnosis of PsA. Joint pain in women, heel pain, and any duration of morning joint stiffness or back stiffness as recorded by the physician, but not the presence of back pain in general, were also associated with subsequent development of PsA. Furthermore, this study highlights the importance of assessing not only the pattern, but also the intensity of symptoms, since the gradual worsening in 4 assessed domains was associated with subsequent development of PsA. The presence of arthralgia predicted future PsA in women but not in men. The reason for this difference between the sexes in unclear. Women with PsA tend to have higher pain scores compared with men (24, 25) , so it is possible that they have a lower pain threshold or that women feel less inhibited about reporting pain than men.
Pain and stiffness, although not specific, are 2 domains that are commonly taken into consideration by rheumatologists when assessing a patient with suspected PsA, while the assessment of fatigue is often neglected. In our study, ;25% of the participants had fatigue scores that are considered to indicate severe fatigue in the general population (mFSS .5). Furthermore, having high fatigue scores was a strong and early predictor of PsA. Fatigue is an important symptom in patients with PsA (26) . In a previous study, fatigue explained a considerable proportion of the patient-physician discrepancy in global assessments of PsA disease activity (27) . Recently, the domain was included in the inner circle of the new core domains for PsA that was endorsed by Outcome Measures in Rheumatology, which suggests that it should be measured in every clinical trial in PsA (28) . Overall, these findings highlight the need to consider fatigue as an early symptom of imminent PsA that precedes the onset of more specific symptoms of the disease such as joint pain and stiffness.
In this study, we used cut points that were defined by the distribution of the scores of the various patientreported outcomes. This strategy was used due to the lack of accepted cut points for abnormality in PsA for the various domains. A sensitivity analysis that assessed higher cut points showed similar results, except for pain. Using a higher cut point for pain at baseline was found to be a better predictor of the subsequent development of PsA. Studies in patients with acute and chronic pain have suggested that VAS scores for pain that exceed 3 and 5 correspond to moderate and severe pain, respectively (29, 30) , suggesting that the chosen cut point for defining a high level of pain (VAS score .2) may have been too low. The selected cut point for fatigue matched previous definitions of moderate-to-severe fatigue (mFSS .5) and severe fatigue (mFSS .7) in patients with PsA (21). Similarly, the selected cut point for psychological distress (SF-36 MCS ,42) was shown to have a sensitivity and specificity of 74% and 81%, respectively, in identifying patients with depression (31) . Thus, overall, the majority of the selected cut points for the different domains correlate well with validated indicators of severity.
Our study had several limitations. The number of symptoms assessed in our study was limited to the major domains assessed in clinical trials and observational studies in PsA. We did not collect data on the full range of symptoms experienced by patients with early PsA. Additionally, we did not have detailed information about the joint sites or body parts affected, symmetry, or duration of symptoms reported by the study participants. Second, we acknowledge that the diagnosis of some of the features of PsA, such as spondylitis or enthesitis, may require imaging studies. We did not perform such imaging studies in all patients since the diagnostic process relied on clinical judgment of the assessing rheumatologist, similar to usual clinical practice. Therefore, MRI was not performed in all patients with inflammatory back pain and normal findings on radiography of the spine, which may have resulted in underdiagnosis of patients with nonradiographic SpA. However, the majority of patients who developed PsA in our study had peripheral arthritis, with or without axial involvement, and only a minority had pure axial involvement or enthesitis without peripheral arthritis. In fact, none of the patients who reported having inflammatory back pain at baseline developed subsequent PsA. Last, it is possible that some of the patients had inflammatory arthritis at enrollment that could have been detected by more sensitive imaging studies such as ultrasound or MRI. However, according to the CASPAR criteria, patients are classified as having PsA only if they have clinical evidence of inflammatory peripheral arthritis, spondylitis, or enthesitis, which require objective findings on physical examination (18) . Since the musculoskeletal assessment was very comprehensive and included careful attention to all potential clinical features of PsA, we believe that it represents at least the usual clinical practice for diagnosis of PsA in rheumatology.
The major strength of this study is its prospective longitudinal nature. Patients were followed up over time according to standard protocols, including patient-reported outcomes, which allowed the assessment of various important PsA domains while avoiding recall bias. Additionally, all participants were assessed at each visit by rheumatologists experienced in assessing PsA patients. Imaging studies were ordered as clinically indicated and relied on the physicians' judgment, which reflects usual clinical practice. To the best of our knowledge, this is the first study that assessed the complex of symptoms affecting patients in the preclinical phases of PsA.
In summary, our study found that patients who present with high levels of fatigue, pain, and stiffness and those who show gradual worsening of these symptoms as well as worsening of physical function and psychological distress should be followed up more closely even in the absence of objective findings of PsA, since they are more likely to develop the disease in subsequent years. Further research is required to better define the earliest phases of PsA in order to improve the identification of psoriasis patients who will go on to develop PsA and might be appropriate candidates for early interventions.
